Rituximab for noninfectious uveitis

Elisabetta Miserocchi, Giulio Modorati

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Citations (Scopus)

Abstract

Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen expressed on B cells. This drug has been successfully employed in the treatment of non-Hodgkin's lymphoma and different systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener's) and anti-neutrophil cytoplasmic antibody-associated vasculitis. At present, RTX may be used in patients with rheumatoid arthritis who qualify for treatment with tumor necrosis factor blockers and have had an inadequate response or intolerance to one or more of these agents. In ophthalmology, there is a growing amount of literature which suggests that RTX may be useful for inflammatory ocular diseases. Only few cases have been reported on treatment of ocular inflammatory disease mostly refractory scleritis, peripheral ulcerative keratitis, uveitis in adulthood and in children with juvenile idiopathic arthritis. RTX has also been employed in ocular surface diseases such as ocular cicatricial pemphigoid and conjunctival lymphoma. The tolerability and safety of RTX is good with the most common adverse events encountered being infusion reactions. RTX may be effective in the treatment of ocular inflammatory diseases, in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation and uveitis. Although further studies are needed to assess the efficacy of RTX and the exact dosing regimen, RTX may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and other biologic agents.

Original languageEnglish
Title of host publicationDevelopments in Ophthalmology
PublisherS. Karger AG
Pages98-109
Number of pages12
Volume51
ISBN (Print)9783805599870, 9783805599863
DOIs
Publication statusPublished - Apr 20 2012

Fingerprint

Uveitis
Eye Diseases
Rheumatoid Arthritis
CD20 Antigens
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Benign Mucous Membrane Pemphigoid
Scleritis
Corneal Ulcer
Therapeutics
Granulomatosis with Polyangiitis
Juvenile Arthritis
Rituximab
Biological Factors
Ophthalmology
Systemic Lupus Erythematosus
Non-Hodgkin's Lymphoma
Autoimmune Diseases
Lymphoma
B-Lymphocytes
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Cite this

Miserocchi, E., & Modorati, G. (2012). Rituximab for noninfectious uveitis. In Developments in Ophthalmology (Vol. 51, pp. 98-109). S. Karger AG. https://doi.org/10.1159/000336188

Rituximab for noninfectious uveitis. / Miserocchi, Elisabetta; Modorati, Giulio.

Developments in Ophthalmology. Vol. 51 S. Karger AG, 2012. p. 98-109.

Research output: Chapter in Book/Report/Conference proceedingChapter

Miserocchi, E & Modorati, G 2012, Rituximab for noninfectious uveitis. in Developments in Ophthalmology. vol. 51, S. Karger AG, pp. 98-109. https://doi.org/10.1159/000336188
Miserocchi E, Modorati G. Rituximab for noninfectious uveitis. In Developments in Ophthalmology. Vol. 51. S. Karger AG. 2012. p. 98-109 https://doi.org/10.1159/000336188
Miserocchi, Elisabetta ; Modorati, Giulio. / Rituximab for noninfectious uveitis. Developments in Ophthalmology. Vol. 51 S. Karger AG, 2012. pp. 98-109
@inbook{f88ec2db13534b008ef21fd33d2baec8,
title = "Rituximab for noninfectious uveitis",
abstract = "Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen expressed on B cells. This drug has been successfully employed in the treatment of non-Hodgkin's lymphoma and different systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener's) and anti-neutrophil cytoplasmic antibody-associated vasculitis. At present, RTX may be used in patients with rheumatoid arthritis who qualify for treatment with tumor necrosis factor blockers and have had an inadequate response or intolerance to one or more of these agents. In ophthalmology, there is a growing amount of literature which suggests that RTX may be useful for inflammatory ocular diseases. Only few cases have been reported on treatment of ocular inflammatory disease mostly refractory scleritis, peripheral ulcerative keratitis, uveitis in adulthood and in children with juvenile idiopathic arthritis. RTX has also been employed in ocular surface diseases such as ocular cicatricial pemphigoid and conjunctival lymphoma. The tolerability and safety of RTX is good with the most common adverse events encountered being infusion reactions. RTX may be effective in the treatment of ocular inflammatory diseases, in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation and uveitis. Although further studies are needed to assess the efficacy of RTX and the exact dosing regimen, RTX may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and other biologic agents.",
author = "Elisabetta Miserocchi and Giulio Modorati",
year = "2012",
month = "4",
day = "20",
doi = "10.1159/000336188",
language = "English",
isbn = "9783805599870",
volume = "51",
pages = "98--109",
booktitle = "Developments in Ophthalmology",
publisher = "S. Karger AG",

}

TY - CHAP

T1 - Rituximab for noninfectious uveitis

AU - Miserocchi, Elisabetta

AU - Modorati, Giulio

PY - 2012/4/20

Y1 - 2012/4/20

N2 - Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen expressed on B cells. This drug has been successfully employed in the treatment of non-Hodgkin's lymphoma and different systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener's) and anti-neutrophil cytoplasmic antibody-associated vasculitis. At present, RTX may be used in patients with rheumatoid arthritis who qualify for treatment with tumor necrosis factor blockers and have had an inadequate response or intolerance to one or more of these agents. In ophthalmology, there is a growing amount of literature which suggests that RTX may be useful for inflammatory ocular diseases. Only few cases have been reported on treatment of ocular inflammatory disease mostly refractory scleritis, peripheral ulcerative keratitis, uveitis in adulthood and in children with juvenile idiopathic arthritis. RTX has also been employed in ocular surface diseases such as ocular cicatricial pemphigoid and conjunctival lymphoma. The tolerability and safety of RTX is good with the most common adverse events encountered being infusion reactions. RTX may be effective in the treatment of ocular inflammatory diseases, in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation and uveitis. Although further studies are needed to assess the efficacy of RTX and the exact dosing regimen, RTX may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and other biologic agents.

AB - Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen expressed on B cells. This drug has been successfully employed in the treatment of non-Hodgkin's lymphoma and different systemic autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, granulomatosis with polyangiitis (Wegener's) and anti-neutrophil cytoplasmic antibody-associated vasculitis. At present, RTX may be used in patients with rheumatoid arthritis who qualify for treatment with tumor necrosis factor blockers and have had an inadequate response or intolerance to one or more of these agents. In ophthalmology, there is a growing amount of literature which suggests that RTX may be useful for inflammatory ocular diseases. Only few cases have been reported on treatment of ocular inflammatory disease mostly refractory scleritis, peripheral ulcerative keratitis, uveitis in adulthood and in children with juvenile idiopathic arthritis. RTX has also been employed in ocular surface diseases such as ocular cicatricial pemphigoid and conjunctival lymphoma. The tolerability and safety of RTX is good with the most common adverse events encountered being infusion reactions. RTX may be effective in the treatment of ocular inflammatory diseases, in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation and uveitis. Although further studies are needed to assess the efficacy of RTX and the exact dosing regimen, RTX may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and other biologic agents.

UR - http://www.scopus.com/inward/record.url?scp=84925855475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925855475&partnerID=8YFLogxK

U2 - 10.1159/000336188

DO - 10.1159/000336188

M3 - Chapter

SN - 9783805599870

SN - 9783805599863

VL - 51

SP - 98

EP - 109

BT - Developments in Ophthalmology

PB - S. Karger AG

ER -